A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inducible Urticaria
Chronic Spontaneous Urticaria

Interventions

DRUG: EDP-978
DRUG: Placebo

Sponsor

Enanta Pharmaceuticals, Inc